EP1659113A1 — Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1)
Assigned to Evotec OAI AG · Expires 2006-05-24 · 20y expired
What this patent protects
The invention relates to sulfonamide compounds of formula (I) wherein A, B, R 1 and X 1 to X 3 have the meaning as cited in the description and the claims. For example A is biphenyl, B is 2-morpholin-4-yl-2-oxo-ethyl, R 1 is H and X 1 to X 3 are CH. Said compounds are…
USPTO Abstract
The invention relates to sulfonamide compounds of formula (I) wherein A, B, R 1 and X 1 to X 3 have the meaning as cited in the description and the claims. For example A is biphenyl, B is 2-morpholin-4-yl-2-oxo-ethyl, R 1 is H and X 1 to X 3 are CH. Said compounds are useful as 11β-HSD1 inhibitors. The invention also relates to the preparation of such compounds as well as the production and use as medicament.
Drugs covered by this patent
- Tradjenta (LINAGLIPTIN) · Boehringer Ingelheim
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.